K
0.103
-0.56 (-84.44%)
| Previous Close | 0.662 |
| Volume | 27,618,090 |
| Price / Sales | 0.090 |
| 52 Weeks Range |
| Profit Margin | -43.99% |
| Operating Margin (TTM) | -110.80% |
| Diluted EPS (TTM) | -11.87 |
| Quarterly Revenue Growth (YOY) | -9.40% |
| Current Ratio (MRQ) | 1.33 |
| Operating Cash Flow (TTM) | -122.75 M |
| Levered Free Cash Flow (TTM) | -72.22 M |
| Return on Assets (TTM) | -44.76% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Karyopharm Therapeutics Inc. | Mixed | Bearish |
AIStockmoo Score
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | 2.8 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -2.0 |
| Relative Valuation | NA |
| Financial Health | -3.7 |
| Macro Environment | -2.8 |
| AI Insight | NA |
| AI Technical | NA |
| Weighted Average | -0.70 |
Select this tab to load the latest available analysis.
|
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company focused on novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company conducts research focused on intracellular communication between the nucleus and cytoplasm and has developed small-molecule compounds that inhibit exportin 1 (XPO1), a nuclear export protein. It is focused on marketing XPOVIO (selinexor). |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 6.33% |
| % Held by Institutions | 42.78% |
No data within this time range.
No data within this time range.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |